UPDATE 1-Samsung, Biogen version of AbbVie’s Humira approved in Europe

Aug 24 (Reuters) – A biosimilar version of AbbVie Inc’sblockbuster arthritis drug Humira, produced by a jointventure of Biogen Inc and Samsung Biologics, was approved by European Union regulators, thepartners said on Thursday.
The post UPDATE 1-Samsung, Biogen version of AbbVie’s Humira approved in Europe appeared first on RocketNews | Top News Stories From Around the Globe.